Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable.
SUMMARY
Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable.
The search for new therapeutic targets is therefore essential. Here we show that a higher expression of the lysine methyltransferase SETD8, which is responsible for histone H4K20 mono-methylation, is an adverse prognosis factor associated with a poor outcome in two cohorts of newly diagnosed patients. Remarkably, primary malignant plasma cells are particularly addicted to SETD8 activity. Indeed, pharmacological inhibition of this enzyme by the chemical compound UNC0379 demonstrated a significantly higher toxicity in MM cells compared to normal cells from the bone marrow microenvironment. Moreover, RNA sequencing and functional studies revealed that SETD8 inhibition induces a mature non-proliferating plasma cell signature and an activation of the p53 canonical pathway, which together leads to an impairment of myeloma cell proliferation and survival. However, UNC0379 treatment triggers a deadly level of replicative stress in p53 deficient MM cells, indicating that the cytotoxicity associated with SETD8 inhibition is independent of the p53 status. Consistent with this, the combination of UNC0379 with the conventional cytotoxic agent melphalan strongly enhances DNA damage and overcomes drug resistance in myeloma cells.
Thus, targeting SETD8 could be of therapeutic interest to improve MM treatment in highrisk patients independently of the p53 status.
INTRODUCTION
Multiple Myeloma (MM) is a cancer of terminally differentiated plasma cells characterized by bone destruction, renal failure, and anemia 1 . It is the second most common hematological malignancy after non-Hodgkin lymphoma 2 . Over the past 15 years, several advances in treatments have led to a significantly higher survival of intensively treated patients. This involves a large panel of therapeutic agents, including immunomodulatory drugs and proteasome inhibitors, in combination with autologous stem cell transplantation, alkylating agents (melphalan) and glucocorticoids 3 .
Unfortunately, despite the recent progress in MM treatments, most patients will ultimately relapse and develop drug resistance. This cancer thus remains incurable for the majority of patients.
In addition to a wide panel of genetic mutations, recent studies have pinpointed that epigenetic alterations, including aberrant DNA and histone methylation, might be also important players in multiple myeloma development 4 . These recent findings could illuminate new mechanisms central to the genesis of multiple myeloma and offer the possibility to reveal novel approaches and targets for effective therapeutic intervention.
For example, the inhibition of the histone H3K27 methyltransferase EZH2 has recently emerged as a potential strategy for the treatment of myeloma 5 . Moreover, classic epigenetic modulating agents, such as histone decatylase inhibitors and DNA methyltransferase inhibitors, are already tested in as monotherapy or in combination with conventional anti-MM agents 6, 7 . However, the occurrence of important side effects and the appearance of resistance to these drugs increase the need to identify novel epigenetic targets in multiple myeloma and evaluate their pre-clinical perspective. SETD8 (also known as SET8, PR-Set7, KMT5A) has been identified as the epigenetic enzyme responsible for the mono-methylation of histone H4 at lysine 20 (H4K20me1) 8 . SETD8 and H4K20me1 are naturally increased during mitosis and play a critical role in chromatin compaction, gene regulation and cell-cycle progression . In addition, SETD8 could induce the methylation of non-histone proteins, such as the replication factor PCNA and the tumor suppressor p53 11, 12 . While SETD8-mediated methylation of p53 inhibits apoptosis 12 , PCNA methylation by SETD8 might enhance the interaction with the Flap endonuclease FEN1 and promote cell proliferation 11 .
Consistent with this, the overexpression of SETD8 has been reported in many different solid tumors [14] [15] [16] [17] and pharmacological inhibition of SETD8 is sufficient to activate the p53 pro-apoptotic program in neuroblastoma cell lines 18 . This has suggested that this enzyme could be an attractive target to rescue p53 functions in cancers displaying a low incidence of p53 genetic alterations, as it is the case at early stages in multiple myeloma 19 . However, the role of SETD8 and its incidence in the development of multiple myeloma or any hematological malignancies is not known.
Here, we provide evidence that malignant plasma cells are addicted to SETD8 expression, which is associated with a poor outcome independently of changes in the steady state level of histone H4K20me1. Although inducing p53 canonical pathway, we show that the pharmacological inhibition of SETD8 by the chemical compound UNC0379 also triggers cell-cycle defects and apoptosis in myeloma cells deficient for p53. Finally, the combination of UNC0379 with the cytotoxic agent melphalan strongly enhances DNA damage and overcomes drug resistance, suggesting that targeting SETD8 activity could be beneficial to improve multiple myeloma treatment in high-risk patients independently of their mutational status for p53.
RESULTS
SETD8 up-regulation in myeloma is associated with a poor outcome. In order to identify epigenetic factors potentially involved in Multiple Myeloma, we used public affymetrix microarrays gene expression data sets to identify which genes encoding histone-modifying enzymes are differentially expressed between normal bone marrow plasma cells (BMPCs, n=22), purified primary MM cells from newly diagnosed patients (MMCs, n = 345) and human myeloma cell lines (HMCLs, N=42) 19 . As shown in Figure   1A , a significant higher levels of mRNAs encoding the histone H4K20 monomethyltransferase SETD8 was found in HMCLs compared to BMPCs and MMCS ( Fig   1A) . Furthermore, although we did not observe a statistical difference with BMPCs, SETD8 mRNA levels appeared heterogeneous in MMCs ( Figure 1A ) ranging from 65 to 63338 in affymetrix signal. This contrasted SETD8 mRNA levels was not restrained to a particular MM molecular sub-type (supplementary Figure S1 ). Consistent with these observations, immunoblot analysis with specific SETD8 antibody showed that HMCLs and some MMCs displayed higher SETD8 protein levels compared with non-cancerous plasma cells (PC) ( Figure 1B ). These higher SETD8 protein levels were independent to the natural cell-cycle fluctuation of the enzyme 9 , as the levels of the mitotic marker histone H3-S10 phosphorylation were relatively similar in all tested samples ( Figure 1B ).
SETD8 is known as the unique enzyme responsible for the mono-methylation of histone H4 at lysine 20 (H4K20me1) 8 . Yet, the levels of H4K20me1 remained roughly unchanged in HMCLs and MMCs displaying higher SETD8 levels ( Figure 1B) , indicating that SETD8 up-regulation does not trigger an increase in the steady state level of histone H4K20me1 in multiple myeloma. We next investigated the prognostic value of SETD8 up-regulation in two independent cohorts of previously untreated MM patients (UAMS-TT2 n=256 and UAMS-TT3 n=158 cohorts), using Maxstat R algorithm. High SETD8 mRNA levels were predictive of both shorter event free survival and overall survival in the two cohorts ( Figure 1C ). Consistent with these results, SETD8 mRNA levels were significantly increased in patients harboring Chr1q21 gain ( Figure 1D ) or presenting a high gene expression-based proliferation index (GPI) ( Figure 1E ), molecular features being associated with a poor outcome in MM patients. However, SETD8 expression did not correlate with MMC plasma cell labeling index (PCLI) in a cohort of 101 newly diagnosed patients (supplementary Figure S2 ), suggesting that SETD8 up-regulation is likely not a hallmark of MMC proliferation status. Gene set expression analysis (GSEA) of patients with high SETD8 expression highlighted a significant enrichment of genes involved in IRF4 targets, MYC-MAX targets, MAPK pathway and DNA repair (Supplementary Figure S3 , P<0.001), suggesting that SETD8 up-regulation correlates with changes in signaling pathways involved in MM pathophysiology. Furthermore, SETD8 expression is significantly higher in MM cell of patients at relapse compared to newly diagnosed patients, underlining a potential role of SETD8 in drug resistance (Supplementary Figure S4) . Altogether, these data reveal that SETD8 is overexpressed in myeloma and this up-regulation is associated with a poor outcome and deregulation of major signaling pathways in MM patients.
UNC0379-mediated SETD8 inhibition leads to cell-cycle defects and apoptosis in

MMCs.
To determine the biological significance of SETD8 up-regulation in MM pathophysiology, the effects of the small-molecule SETD8 inhibitor UNC0379 were examined in eight different HMCLs representative of the disease. UNC0379 is a well-characterized substrate-competitive inhibitor selective for SETD8 15, 18, 22 . As shown in Figure 2A , UNC0379 treatment was sufficient to inhibit the growth of all HMCLs in a dose dependent manner with an average half maximal inhibitory concentration (IC 50 ) ranging from 1.25 to 6.3 µM (Figure 2A) . To determine the molecular mechanisms of this HMCL growth inhibition, the effects of UNC0379 treatment on SETD8 activity, cell proliferation and survival were examined using immunoblot and flow cytometry assays in XG7 and XG25 MM cell lines, which displayed similar IC 50 values for UNC0379. As shown in Figure 2B , analysis of whole cell extracts after 24 hours of treatment showed a strong decrease in H4K20me1, but not of SETD8 and histone H4, thereby demonstrating the rapid and efficient inhibition of SETD8 activity ( Figure 2B ). In the following hours, this SETD8 inhibition was associated with cell-cycle defects, as shown by an accumulation in G1 phase and a decrease in DNA replication (S) phase 48 hours after treatment ( Figure 2C ). At later time points, these cell cycle defects was followed by the activation of apoptosis, as measured by the appearance of 33% and 26% of annexin-V positive XG7 and XG25 cells ( Figure 2D ).
To confirm that SETD8 is essential for growth and viability of malignant plasma cells, bone marrow (BM) from MM patient samples were cultured with recombinant interleukin 6 in presence or not of UNC0379. Five days after treatment, the percentage of myeloma and non-myeloma cells was then measured by flow cytometry after staining with anti-CD138 antibody that specifically recognizes plasma cells. As shown in Figure   2E , the median number of CD138 positive malignant plasma cells were decreased in a dose-dependent manner, with 50% and 63% of reduction with 2.5 µM and 5 µM of UNC0379 respectively (P = 0.001 and P < 0.0001; N=8), whereas non-tumoral BM cells were less sensitive with a decrease of 26% and 24% at these UNC0379 concentrations.
In addition, to support the feasibility of preclinical studies with SETD8 inhibitors, primary 5T33vv murine MM models 23 were treated with growing concentrations of UNC0379 for 24h hours before cell viability analysis. As observed with human primary MM cells ( Figure 2E ), UNC0379 treatment results in significant reduction of 5T33vv viability in a dose dependent manner (Supplementary Figure S5) . We therefore conclude that malignant plasma cells are particularly addicted to SETD8 activity and that the pharmacological inhibition of this epigenetic enzyme is highly toxic, leading rapidly to cell growth inhibition and apoptosis.
SETD8 inhibition impairs MM cell proliferation together with activation of p53
target gene pathways. SETD8 has been involved in all nuclear processes that use DNA as a matrix, including a critical role in the regulation of gene expression 8 . In order to gain insights into the mechanisms contributing to SETD8-mediated MM cell growth inhibition and death, we therefore performed transcriptome analysis in XG7 and XG25 HMCLs after SETD8 inhibition using RNA sequencing (RNAseq). To identify gene expression alterations caused by SETD8 inhibition in HMCLs, we isolated total RNAs 18 hours after UNC0379 treatment or 48 hours after shRNA-induced SETD8 silencing, when H4K20me1 decrease did not trigger DNA replication defects yet 24, 25 . A common signature of 820 up-regulated genes and 360 down-regulated genes was found in Conversely and consistent with the presence of a functional p53 in XG7 and XG25 cell lines, a significant positive enrichment was found for p53 target genes, including p21 and GADD45A genes, and genes overexpressed in mature BMPCs versus plasmablasts (Figures 3C and 3D). A positive enrichment for genes normally downregulated by c-MYC, EZH2, DNA methylation or histone deacetylases (HDAC) was also observed ( Figure 3C ), which might suggest some impairments of chromatin silencing pathways upon SETD8 inhibition in MM cells. As shown in figure 3E , immunoblot analysis of UNC0379-treated XG7 HMCLs confirmed the increased levels of p53 and p21 proteins upon UNC0379 treatment. However, we did not observe a significant phosphorylation of the histone variant H2A.X ( Figure 3E ), suggesting p53 activation in XG7 MM cells treated with UNC0379 occurs in absence or low level of DNA damage.
Altogether, these results data indicate that the cytotoxic effects of SETD8 inhibition in p53-proficient HMCLs are associated with mature non-proliferating plasma cell transcriptional signature and activation of the p53 canonical pathway.
The cytotoxicity of UNC0379 treatment is not dependent on p53 in malignant plasma cells. Previous studies showed that UNC0379-induced cell death depends on the activation of p53 in neuroblastoma cancer models (NB), thereby rending p53deficient NB cells more resistant to SETD8 inhibition (Veschi et al. 2017 ). To determine whether the cytotoxic effects of the pharmacological inhibition of SEDT8 mediated by UNC0379 was also dependent on p53 activation in MM cells, we compared the UNC0379 response in p53 wild-type HMCLs (n=7) and p53-deficient HMCLs (n=5) 20, 21 that displayed similar SETD8 expression levels ( Figure 4A ). Noted of, there was no significant correlation between SETD8 and P53 expression in HMCLs (Supplementary Figure S7 ). Although IC 50 values for p53-deficient HMCLs following UNC0379 treatment were more heterogeneous, we found no statistical difference with the group of p53 wild-type HMCLs ( Figure 4B ). We also observed no statistical difference in the IC 50 Figure 4D ). This was followed by the appearance of a high percentage of apoptotic cells, similarly to the percentage detected in UNC0379-treated control shRNA XG7 cells displaying p53 activation ( Figure   4E ). Importantly, a similar DNA damage signature was observed in XG1 HMCL naturally harboring a mutated inactive p53 (Supplementary Figure S9) . Thus, these results indicated that UNC0379-induced cytotoxicity in MM cells is independent on p53 status and that a high level of SETD8 likely protects MM cells from spontaneous intrinsic DNA damage and replicative stress.
Pharmacological inhibition of SETD8 synergizes with melphalan. The results
presented above indicate that the pharmacological inhibition of SETD8 could constitute a promising strategy to improve multiple myeloma treatment by increasing DNA damage and genomic instability. To further explore this possibility, we investigated whether SETD8 inhibition could enhance the cytotoxicity of melphalan and overcome resistance to this alkylating agent widely used in MM treatment. To this end, we first measured by FACS the levels of apoptotic cells in sensitive (MelphS) and melphalan-resistance (Figures 3 and 4 ). Finally, in order to support future pre-clinical study, we have shown that a low dose of UNC0379 enhances melphalan-induced cell death and overcomes the resistance associated with this DNA-damaging conventional cytotoxic agent in both p53 wild-type and deficient MM cells ( Figure 5 ). Altogether, these results provide evidence for SETD8 inhibition as a potential novel therapeutic strategy in multiple myeloma independently from the mutational p53 status of these tumors.
An up-regulation of SETD8 is not specific to multiple myeloma, as it has also been observed in different types of solid tumors 11 , such as papillary thyroid cancer 16 , breast carcinoma 14, 26 , and childhood tumors of the nervous system 15, 18 . However, the mechanisms that contribute to elevated levels of SETD8 in cancer still remained unclear. In neuroblastoma, a higher-level of SETD8 could be due in part to DNA copynumber gains at chr12q24, the region that encompasses SETD8 encoding gene 26 .
Another non-exclusive mechanism is related to the deregulation of oncogenic c-MYC pathway, since SETD8 encoding gene has been found as a transcriptional target of c-MYC 27 and functionally required to mediate MYC-induced cell growth 15 . It is widely established that c-MYC is a key regulator in MM with deregulations related to translocations, gains and amplification, mutations in RAS genes and MYC transcription or translation activation 28 . Interestingly, while chr12q24 gains are not present in myeloma, we identified here a significant enrichment of c-MYC/MAX target genes in MM patients characterized by high SETD8 expression, thereby supporting a potential role of this oncogenic pathway in SETD8 deregulation. Furthermore, SETD8 depletion or inhibition results in up-regulation of genes repressed upon c-MYC expression ( Figure   3C ) suggesting that SETD8 might also participate in deregulation of c-MYC functions in multiple myeloma.
An unexpected result of our study is that the up-regulation of SETD8 in malignant plasma cells was not associated with significant changes in the steady state level of the mono-methylation of histone H4K20 (H4K20me1), the main target of SETD8 8 . This result is independent from cell-cycle progression, since changes in the levels of SETD8 do not correlate with cell proliferation ( figure 1B and supplementary figure S2 ). One hypothesis is that an overexpression of the H4K20me1-specific demethylase PHF8, observed in many cancers including hematopoietic malignancies 29, 30 , could attenuate SETD8 activity on histone H4K20 31 . Thus, although we cannot rule out that some local changes in H4K20me1 levels may occur at specific genetic loci, our results indicate that the global level of this epigenetic modification is not a valuable marker of SEDT8 activity and functions in multiple myeloma.
Recent studies have suggested that the role of SETD8 in cancer might involve the methylation of other substrates than histone H4. Thus, Takawa et al. proposed that SEDT8 can methylate the proliferating cell nuclear antigen PCNA and thus favor HeLa cell proliferation 11 ; but this result was never further confirmed in other cell types.
Additionally, SETD8 can induce the mono-methylation of the tumor suppressor p53 at lysine 382 (p53K382), which attenuates its pro-apoptotic and growth arrest functions 12, 18 . Hence, in neuroblastoma, inhibition of SETD8 by UNC0379 leads to cell death in a dependent p53 manner and p53K382 is important for this phenotype 18 . Our RNA-seq and functional studies in MM cells shows that the genetic or pharmacological inhibition of SETD8 leads to the activation of p53 pathway, which correlates with an increased in p53 and p21 protein levels, G1/S arrest followed by cell death. However, in contrast to neuroblastoma 18 , UNC0379-induced cytotoxicity in MM cells is not necessarily dependent on p53 activation and, despite several attempts, we were unable to detect p53K382me1 in MM cells. Few DNA breaks are generally sufficient to activate P53 functions 32, 33 . Since the first impact of loss of SETD8 activity is excessive chromatin relaxation and progressive DNA damage after exit of mitosis 34 , we propose that the activation of p53 we detect in MM cells upon SETD8 inhibition is mainly triggered by cellular stresses during G1 progression. This would also explain why UNC0379mediated SETD8 inhibition is very toxic in P53-deficient MM cells, where the absence of a functional p53-mediated G1 arrest allows damaged cells to pursue into S-phase and accumulate a deadly level of DNA breaks, likely caused by improper replication fork progression 24 . Altogether, our findings are consistent with a model in which UNC0379mediated cell death is triggered by p53 activation in p53-proficient MM cells and rather associated with high replicative stress in cancer cells deficient for p53, thereby rending multiple myeloma sensitive to SEDT8 inhibition whatever the mutational status of p53.
In spite of effective therapeutic protocols developed in MM, drug resistance remains a major concern. In this regard, we report here that high SETD8 expression is Patients' MMCs were purified using anti-CD138 MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and their gene expression profile (GEP) obtained using Affymetrix U133 plus 2.0 microarrays as described 41, 42 . The CEL files and MAS5 files are available in the ArrayExpress public database (E-MTAB-372). The structural chromosomal aberrations, as well as numerical aberrations were assayed by fluorescence in situ hybridization (iFISH). We also used publicly available Affymetrix GEP (Gene Expression Omnibus, accession number GSE2658) of a cohort of 345 purified MMC from previously untreated patients from the University of Arkansas for Medical Sciences (UAMS, Little Rock, AR), termed in the following UAMS-TT2 cohort.
MATERIALS AND METHODS
Primary multiple myeloma cells
These patients were treated with total therapy 2 including HDM and ASCT 43 . We also used Affymetrix data from total therapy 3 cohort (UAMS-TT3; n=158; E-TABM-1138) 44 of 188 relapsed MM patients subsequently treated with bortezomib (GSE9782) from the study by Mulligan et al 45 . The mouse 5T33MMvv cells originated spontaneously in aging C57BL/KaLwRij mice and have since been propagated in vivo by intravenous transfer of the diseased marrow in young syngeneic mice as described 23, 46 .
Treatment of primary MM cells
Bone marrow of patients presenting with previously untreated MM (n = 8) at the university hospital of Montpellier was obtained after patients' written informed consent in accordance with the Declaration of Helsinki and agreement of the Montpellier University Hospital Centre for Biological Resources (DC-2008-417). Mononuclear cells were treated with or without UNC-0379 (1µM, 2.5µM or 5µM) and MMC cytotoxicity were evaluated using anti-CD138-phycoerythrin monoclonal antibody (Immunotech, Marseille, France) as described 47 .
Human Myeloma Cell Lines (HMCLs)
XG human myeloma cell lines (HMCLs) were cultured in the presence of recombinant IL-6 as previously described 20 
Establishment of shRNA expressing HMCLs
Control and p53 shRNA sequences were cloned in the pLenti4-EZ-mIR plasmid as previously described 48 . SETD8 and associated control shRNA sequences were cloned into a puromycin retroviral vector RNAi Ready pSiren as described 24 . Retroviral particles were produced in 293FT cells. Briefly, 293FT cell line was cultured in Dulbecco's modified Eagle's medium and supplemented with 10% defined fetal bovine serum, 500µg/ml geneticin, 4mM L-glutamine, and 1mM MEM sodium pyruvate. The day before transfection, cells were plated into a 10cm tissue culture plate to 90%-95% confluence. 
Growth assays and cell cycle analysis
Apoptosis assays
Cells were cultured in 24-well, flat-bottomed microtiter plates at 10 5 cells per well in RPMI1640-10% FCS or X-VIVO 20 culture medium with or without IL-6 (3ng/mL) and appropriate concentration of chemical drugs. After 4 days of culture, cells were washed twice in PBS and apoptosis was assayed with PE-conjugated Annexin V labeling (BD Biosciences) using a Fortessa flow cytometer (BD) following manufacturer protocols.
RNA sequencing
HMCLs were cultured for 16 hours with or without 5 µM of UNC-0379, or infected with shcontrol or shRNA SETD8 pSIREN vectors for 48h. RNA samples were collected as 
Gene expression profiling and statistical analyses
Gene expression data were normalized with the MAS5 algorithm and analyses processed with GenomicScape (http://www.genomicscape.com) 54 the R.2.10.1 and bioconductor version 2.5 programs 50 . Gene Set Expression Analysis (GSEA) was used to identify genes and pathways differentially expressed between populations. Univariate and multivariate analysis of genes prognostic for patients' survival was performed using the Cox proportional hazard model. Difference in overall survival between groups of patients was assayed with a log-rank test and survival curves plotted using the Kaplan-Meier method (Maxstat R package) 55 .
53BP1 Staining-immunofluorescence microscopy
After deposition on slides using a Cytospin centrifuge, cells were fixed with 4% PFA, permeabilized with 0.5% Triton in PBS and saturated with 5% bovine milk in PBS. The rabbit anti-53BP1 (Novus Biologicals -Littleton, CO, USA -NB100304) antibody was diluted 1/300 in 5% bovine milk in PBS, and deposited on cytospins for 60 minutes at room temperature. Slides were washed twice and anti-rabbit alexa 488-conjugated antibody (diluted 1/500 in 5% bovine milk in PBS) was added for 60 minutes at room temperature. Slides were washed and mounted with Vectashield and 1% DAPI. Images and fluorescence were captured with a ZEISS Axio Imager Z2 microscope (X63 objective) (Oberkochen, Germany), analyzed with Omero (omero.mri.cnrs.fr) server and ImageJ software. 
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